drugset
drugset / Trial / NCT05809024

Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy

NCT05809024 ↗

Phase 4 Unknown 100 enrolled Yongsheng Wang Jiangsu HengRui Medicine Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment

Summary

Select the appropriate population for adding CDK4/6 inhibitors therapy in high risk early HR+/HER2-breast cancer based on molecular detection

Timeline

Start
2023-03-01
Primary completion
2025-03-25
Completion
2026-03-25

Drugs

EvaluationDrugModalityDoseRoute
Background Letrozole Other / unclassified — —

Indications

female breast carcinoma hormone receptor-positive breast cancer